Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vomiting 12Nausea 9Neoplasms 6Uterine Cervical Neoplasms 3Leukemia, Myeloid, Acute 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Sezary Syndrome 1Seminoma 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Pediatric Solid Tumor, Unspecified, Protocol Specific 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

fosaprepitant 1Prochlorperazine 1Preoperative Exercise 1Ondansetron 1Olanzapine 1Neurokinin-1 Receptor Antagonists 1FloSeal Matrix 1Ferric Oxide, Saccharated 1Enhanced Recovery After Surgery 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gynecologic Cancer × Ondansetron × Clear all
NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated
62 enrolled 16 charts
Gynecologic

Gynecologic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡